Cholecystokinin modulation of locomotor behavior in rats is sensitized by chronic amphetamine and chronic restraint stress exposure

Brain Research

Volumn 1001, Issue 1-2, 2004, Pages 95-107

  Wunderlich, Glen R ^a,c   Rotzinger, Susan ^a,b   Bush, David E A ^a,d   DeSousa, Norberto J ^a,c   Vaccarino, Franco J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c Boehringer Ingelheim   (Canada)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Amphetamine; Cholecystokinin; Locomotion; PD 140548; Psychostimulant; Restraint; Sensitization; Stress

Indexed keywords

ALPHA METHYL N [(TRICYCLO[3.3.1.1 3,7]DEC 2 YLOXY)CARBONYL]TRYPTOPHYL DEXTRO 3 BENZYL BETA ALANINE; AMPHETAMINE; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMOBILIZATION STRESS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIMBIC SYSTEM; LOCOMOTION; MALE; NERVE CELL; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SENSITIZATION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 1242314878     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.10.064     Document Type: Article

References (53)

1. Antelman S.M., Eichler A.J., Black C.A., Kocan D. Interchangeability of stress and amphetamine in sensitization. Science. 207:1980;329-331.
2. Beinfeld M.C. An introduction to neuronal cholecystokinin. Peptides. 22:2001;1200.
3. Beinfeld M.C., Connolly K., Pierce R.C. OLETF (Otsuka Long-Evans Tokushima Fatty) rats that lack the CCK 1 (A) receptor develop less behavioral sensitization to repeated cocaine treatment than wild type LETO (Long Evans Tokushiam Otsuka) rats. Peptides. 22:2001;1285-1290.
4. Beinfeld M.C., Connolly K., Pierce R.C. Cocaine treatment increases extracellular cholecystokinin (CCK) in the nucleus accumbens shell of awake, freely moving rats, an effect that is enhanced in rats that are behaviorally sensitized to cocaine. J. Neurochem. 81:2002;1021-1027.
5. Crawley J.N. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. J. Neurosci. 12:1992;3380-3391.
6. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides. 15:1994;731-755.
7. Crawley J.N., Stivers D.W., Hommer D.W., Skirboll L., Paul S.M. Antagonists of central and peripheral behavioral actions of cholecystokinin. J. Pharmacol. Exp. Ther. 236:1986;320-330.
8. DeSousa N.J., Wunderlich G.R., De Cabo C., Vaccarino F.J. The expression of behavioral sensitization to amphetamine: role of CCKA receptors. Pharmacol. Biochem. Behav. 62:1999;31-37.
9. Ding X.Z., Bayer B.M. Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine. Brain Res. 625:1993;139-144.
10. Faris P.L., Beinfeld M.C., Scallet A.C., Johannessen J.N., Olney J.W. Increase in hypothalamic cholecystokinin following acute and chronic morphine. Brain Res. 367:1986;405-407.
11. Ghijsen W.E.J.M., Leenders A.G.M., Wiegant V.M. Regulation of cholecystokinin release from central nerve terminals. Peptides. 22:2001;1213-1221.
12. Giardino L., Bettelli C., Pozza M., Calza L. Regulation of CCK mRNA expression in the rat brain by stress and treatment with sertraline, a selective serotonin re-uptake inhibitor. Brain Res. 824:1999;304-307.
13. Hahn B., Zacharko R.M., Anisman H. Alterations of amphetamine elicited perseveration and locomotor excitation following acute and repeated stressor application. Pharmacol. Biochem. Behav. 25:1986;29-33.
14. Haile C.N., Grand P.T., Kosten T.A. Chronic unpredictable stress, but not chronic predictable stress, enhances the sensitivity to the behavioral effects of cocaine in rats. Psychopharmacology (Berl.). 154:2001;213-220.
15. Herman J.P., Stinus L., Le Moal M. Repeated stress increases locomotor response to amphetamine. Psychopharmacology (Berl.). 84:1984;431-435.
16. Higgins G.A., Sills T.L., Tomkins D.M., Sellers E.M., Vaccarino F.J. Evidence for the contribution of CCKB receptor mechanisms to individual differences in amphetamine-induced locomotion. Pharmacol. Biochem. Behav. 48:1994;1019-1024.
17. Hokfelt T., Skirboll L., Rehfeld J.F., Goldstein M., Markey K., Dann O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience. 5:1980;2093-2124.
18. Hokfelt T., Blacker D., Broberger C., Herrera-Marschitz M., Snyder G., Fisone G., Cortes R., Morino P., You Z.B., Ogren S.O. Some aspects on the anatomy and function of central cholecystokinin systems. Pharmacol. Toxicol. 91:2002;382-386.
19. Honda T., Wada E., Battey J.F., Wank S.A. Differential gene expression of CCKA and CCKB receptors in the rat brain. Mol. Cell. Neurosci. 4:1993;143-154.
20. Hsu S.M., Raine L., Fanger H. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29:1981;577-580.
21. Hurd Y.L., Lindefors N., Brodin E., Brene S., Persson H., Ungerstedt U., Hokfelt T. Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission. Brain Res. 578:1992;317-326.
22. Kalivas P.W., Duffy P. Similar effects of daily cocaine and stress on mesocorticolimbic dopamine neurotransmission in the rat. Biol. Psychiatry. 25:1989;913-928.
23. Kariya K., Tanaka J., Nomura M. Systemic administration of CCK-8S, but not CCK-4, enhances dopamine turnover in the posterior nucleus accumbens: a microdialysis study in freely moving rats. Brain Res. 657:1994;1-6.
24. Kim H.Y., Ha J.Y., Whang W.W., Kim H.T., Pyun K.H., Cho S.Y., Hahm D.H., Lee H.J., Shim I. Expression of neuropeptide Y and cholecystokinin in the rat brain by chronic mild stress. Brain Res. 983:2003;201-208.
25. Kirk R.E. Experimental Design: Procedures for the Behavioral Sciences. 1995;Brooks/Cole Publishing, Pacific Grove.
26. Kolta M.G., Shreve P., De Souza V., Uretsky N.J. Time course of the development of the enhanced behavioral and biochemical responses to amphetamine after pretreatment with amphetamine. Neuropharmacology. 24:1985;823-829.
27. Kolta M.G., Shreve P., Uretsky N.J. Effect of pretreatment with amphetamine on the interaction between amphetamine and dopamine neurons in the nucleus accumbens. Neuropharmacology. 28:1989;9-14.
28. Lanca A.J., De Cabo C., Arifuzzaman A.I., Vaccarino F.J. Cholecystokinergic innervation of nucleus accumbens subregions. Peptides. 19:1998;859-868.
29. Leyton M., Stewart J. Preexposure to foot-shock sensitizes the locomotor response to subsequent systemic morphine and intra-nucleus accumbens amphetamine. Pharmacol. Biochem. Behav. 37:1990;303-310.
30. Marshall F.H., Barnes S., Hughes J., Woodruff G.N., Hunter J.C. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J. Neurochem. 56:1991;917-922.
31. Mercer L.D., Beart P.M. Histochemistry in rat brain and spinal cord with an antibody directed at the cholecystokininA receptor. Neurosci. Lett. 225:1997;97-100.
32. Mercer L.D., Le V.Q., Nunan J., Jones N.M., Beart P.M. Direct visualization of cholecystokinin subtype2 receptors in rat central nervous system using anti-peptide antibodies. Neurosci. Lett. 293:2000;167-170.
33. Ortiz J., Fitzgerald L.W., Lane S., Terwilliger R., Nestler E.J. Biochemical adaptations in the mesolimbic dopamine system in response to repeated stress. Neuropsychopharmacology. 14:1996;443-452.
34. Paulson P.E., Robinson T.E. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse. 19:1995;56-65.
35. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 3rd ed. 1997;Academic Press, New York.
36. Robinson T.E., Becker J.B. Behavioral sensitization is accompanied by an enhancement in amphetamine-stimulated dopamine release from striatal tissue in vitro. Eur. J. Pharmacol. 85:1982;253-254.
37. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 396:1986;157-198.
38. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Brain Res. Rev. 18:1993;247-291.
39. Robinson T.E., Angus A.L., Becker J.B. Sensitization to stress: the enduring effects of prior stress on amphetamine-induced rotational behavior. Life Sci. 37:1985;1039-1042.
40. Robinson T.E., Jurson P.A., Bennett J.A., Bentgen K.M. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res. 462:1988;211-222.
41. Rotzinger S., Vaccarino F.J. Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. J. Psychiatry Neurosci. 28:2003;171-181.
42. Rotzinger S., Bush D.E.A., Vaccarino F.J. Cholecystokinin modulation of mesolimbic dopamine function: regulation of motivated behaviour. Pharmacol. Toxicol. 91:2002;404-413.
43. Segal D.S., Mandell A.J. Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol. Biochem. Behav. 2:1974;249-255.
44. Seroogy K., Fallon J.H. Forebrain projections from cholecystokinin- immunoreactive neurons in the rat midbrain. J. Comp. Neurol. 279:1989;415-435.
45. Seroogy K., Dangaran K., Lim S., Haycock J.W., Fallon J.H. Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivity project to forebrain regions. J. Comp. Neurol. 279:1989;297-414.
46. Singh L., Field M.J., Hill D.R., Horwell D.C., McKnight A.T., Roberts E., Tang K.W., Woodruff G.N. Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists. Eur. J. Pharmacol. 286:1995;185-191.
47. Sorg B.A., Kalivas P.W. Effects of cocaine and footshock stress on extracellular dopamine levels in the ventral striatum. Brain Res. 559:1991;29-36.
48. Vaccarino F.J., Rankin J. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function. Behav. Neurosci. 103:1989;831-836.
49. 3H]dopamine efflux from rat nucleus accumbens. Neuropeptides. 13:1989;43-50.
50. Voigt M.M., Wang R.Y., Westfall T.C. The effects of cholecystokinin on the in vivo release of newly synthesized [3H]dopamine from the nucleus accumbens of the rat. J. Neurosci. 5:1985;2744-2749.
51. Wolf M.E., White F.J., Nassar R., Brooderson R.J., Khansa M.R. Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization. J. Pharmacol. Exp. Ther. 264:1993;249-255.
52. Wotherspoon G., Savery D., Priestley J.V., Rattray M. Repeated administration of MDMA down-regulates preprocholecystokinin mRNA expression but not tyrosine hydroxylase mRNA expression in neurones of the rat substantia nigra. Brain Res. Mol. Brain Res. 25:1994;34-40.
53. Wunderlich G.R., De Sousa N.J., Vaccarino F.J. Cholecystokinin modulates both the development and the expression of behavioral sensitization to amphetamine in the rat. Psychopharmacology (Berl.). 151:2000;283-290.